Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THDBH120 Phase Ib in Obesity
NCT06951945Phase 1Completed
- Sponsor
- Tonghua Dongbao
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing THDBH120 injection with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s) at 78 days. Started Jul 2024; status: completed.
02
Drugs
THDBH120
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06951945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951945.